CN1194741C - 一种灯盏细辛复方药剂 - Google Patents
一种灯盏细辛复方药剂 Download PDFInfo
- Publication number
- CN1194741C CN1194741C CN 02153750 CN02153750A CN1194741C CN 1194741 C CN1194741 C CN 1194741C CN 02153750 CN02153750 CN 02153750 CN 02153750 A CN02153750 A CN 02153750A CN 1194741 C CN1194741 C CN 1194741C
- Authority
- CN
- China
- Prior art keywords
- crude drug
- treatment
- ginseng
- radix
- herba erigerontis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 100
- 150000001875 compounds Chemical class 0.000 title claims abstract description 13
- 241001013934 Erigeron breviscapus Species 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 37
- 239000000284 extract Substances 0.000 claims abstract description 30
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 235000008434 ginseng Nutrition 0.000 claims abstract description 20
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 14
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000006187 pill Substances 0.000 claims abstract description 8
- 241000208340 Araliaceae Species 0.000 claims description 18
- 241000180649 Panax notoginseng Species 0.000 claims description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 18
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 12
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 241000238370 Sepia Species 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 abstract description 32
- 238000002360 preparation method Methods 0.000 abstract description 21
- 208000006011 Stroke Diseases 0.000 abstract description 13
- 206010008118 cerebral infarction Diseases 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 201000004810 Vascular dementia Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000007796 conventional method Methods 0.000 abstract description 3
- 238000007670 refining Methods 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 3
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 238000002481 ethanol extraction Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 25
- 239000000796 flavoring agent Substances 0.000 description 16
- 235000019634 flavors Nutrition 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 206010008190 Cerebrovascular accident Diseases 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 11
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 5
- 229940000425 combination drug Drugs 0.000 description 5
- 230000002008 hemorrhagic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 5
- 229960002855 simvastatin Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 4
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 4
- 229930190376 scutellarin Natural products 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008828 contractile function Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000010152 Huntington disease-like 3 Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 229940093252 sorbitrate Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
指标 | A组 | B组 | ||||||
例数 | 显效(%) | 有效(%) | 总有效(%) | 例数 | 显效(%) | 有效(%) | 总有效(%) | |
TC | 32 | 78.1 | 12.5 | 90.6 | 31 | 83.9 | 6.5 | 90.3 |
TG | 32 | 40.6 | 18.8 | 59.4 | 31 | 45.2 | 22.6 | 67.3 |
HDL | 32 | 37.5 | 18.8 | 56.3 | 31 | 32.3 | 9.7 | 41.9 |
(TC-HDL)/HDL | 32 | 90.6 | 3.1 | 93.8 | 31 | 87.1 | 6.5 | 93.5 |
观察指标 | 组别 | 例数 | 治疗前 | 治疗4周 | 治疗6周 |
TC(mmol/L) | A | 32 | 6.40±2.08 | 4.47±1.15 | 4.32±1.38 |
B | 31 | 6.54±2.14 | 4.55±1.02 | 4.01±0.99 | |
TG(mmol/L) | A | 32 | 2.43±1.34 | 1.92±1.26 | 1.82±1.14 |
B | 31 | 2.75±2.22 | 2.30±1.93 | 1.92±1.33 | |
LDL-C(mmol/L) | A | 32 | 3.57±1.57 | 2.38±0.95 | 2.17±0.81 |
B | 31 | 3.61±1.61 | 2.43±0.74 | 2.07±0.64 | |
HDL-C(mmol/L) | A | 32 | 1.22±0.09 | 1.28±0.21 | 1.29±0.28 |
B | 31 | 1.23±0.02 | 1.31±0.32 | 1.33±0.35 | |
TC-HDL/HDL | A | 32 | 4.42±1.74 | 2.86±1.52 | 2.53±1.47 |
B | 31 | 4.46±1.55 | 2.63±1.26 | 2.21±1.14 | |
HDL2-C(mmol/L) | A | 32 | 0.43±0.12 | 0.45±0.14 | 0.46±0.13 |
B | 31 | 0.44±0.14 | 0.42±0.10 | 0.43±0.10 | |
HDL3-C(mmol/L) | A | 32 | 0.83±0.24 | 0.86±0.25 | 0.88±0.24 |
B | 31 | 0.79±0.27 | 0.89±0.24 | 0.90±0.28 | |
Apo A(g/L) | A | 32 | 1.10±0.26 | 1.12±0.23 | 1.14±0.22 |
B | 31 | 1.11±0.22 | 1.17±0.30 | 1.16±0.20 | |
Apo B(g/L) | A | 32 | 0.92±0.17 | 0.93±0.46 | 0.93±0.63 |
B | 31 | 0.97±0.22 | 0.82±0.26 | 0.80±0.21 |
组别 | 例数 | 基本痊愈(例) | 显效(例) | 有效(例) | 无效(例) | 有效率(%) | |
D胶囊 | 出血中风 | 42 | 32 | 5 | 3 | 2 | 96.15 |
缺血中风 | 48 | 23 | 18 | 5 | 2 | 95.85 | |
脑血康 | 出血中风 | 22 | 1 | 11 | 6 | 4 | 83.98 |
缺血中风 | 27 | 1 | 5 | 15 | 6 | 83.79 |
组别 | 例数 | 全血粘度(mPa/s) | 血浆粘度(mPa/s) | 纤维蛋白原(mg%) | 红细胞电泳(s) | 红细胞压积(%) | |
D胶囊 | 治疗前 | 52 | 7.26±2.90 | 1.78±0.40 | 339.15±106.01 | 16.86±2.82 | 48.33±9.40 |
治疗后 | 52 | 5.83±1.48 | 1.55±0.37 | 336.80±68.30 | 15.66±2.70 | 39.92±7.28 | |
脑血康 | 治疗前 | 27 | 7.08±2.12 | 1.79±0.11 | 338.60±67.79 | 15.60±5.11 | 46.95±5.85 |
治疗后 | 27 | 6.46±2.02 | 1.70±0.12 | 322.45±54.17 | 16.75±2.08 | 41.56±4.55 |
组别 | 例数 | 全血粘度(mPa/s) | 血浆粘度(mPa/s) | 纤维蛋白原(mg%) | 红细胞电泳(s) | 红细胞压积(%) | |
D胶囊 | 治疗前 | 48 | 7.89±2.28 | 1.77±0.52 | 395.82±94.84 | 15.40±2.72 | 47.90±12.11 |
治疗后 | 48 | 6.38±1.76 | 1.55±0.49 | 327.15±70.00 | 16.20±2.58 | 40.16±7.15 | |
脑血康 | 治疗前 | 33 | 7.45±1.55 | 1.84±0.11 | 333.28±84.47 | 17.40±3.82 | 45.95±5.08 |
治疗后 | 33 | 6.63±1.93 | 1.76±0.1** | 319.98±71.07 | 17.51±3.74 | 42.33±3.87 |
组别 | 例数 | 肩关节肌力 | 髋关节肌力 | 神志状态 | 语言表达 | |
D胶囊 | 治疗前 | 100 | 2.98±1.04 | 2.83±1.02 | 0.54±0.98 | 1.69±1.44 |
治疗后 | 100 | 0.89±1.11 | 0.37±0.73 | 0.02±0.17 | 0.12±0.52 | |
脑血康 | 治疗前 | 60 | 2.74±1.19 | 2.45±1.24 | 0.20±0.55 | 1.30±1.29 |
治疗后 | 60 | 1.26±1.58 | 1.15±1.16 | 0.02±0.13 | 0.36±0.70 |
组别 | 例数 | 完全吸收例(%) | 部分吸收例(%) |
D胶囊 | 52 | 40(76.92) | 12(23.08) |
脑血康 | 27 | 20(74.08) | 7(25.32) |
组别 | 例数 | 梗死范围缩小好转例(%) |
D胶囊 | 48 | 40(83.38) |
脑血康 | 33 | 28(84.84) |
I组 | II组 | |||
治疗前 | 治疗后 | 治疗前 | 治疗后 | |
SV(ml/次) | 67±18 | 76±22 | 66±19 | 68±23 |
CO(L/min) | 5.2±2.0 | 6.0±2.1 | 5.4±1.9 | 5.5±1.8 |
CI(L/min*m2) | 2.6±1.2 | 3.2±1.4 | 2.7±1.3 | 2.8±1.5 |
EF(%) | 53±12 | 61±14 | 54±11 | 57±13 |
FS(%) | 29±8 | 34±9 | 30±8 | 32±9 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02153750 CN1194741C (zh) | 2002-12-04 | 2002-12-04 | 一种灯盏细辛复方药剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02153750 CN1194741C (zh) | 2002-12-04 | 2002-12-04 | 一种灯盏细辛复方药剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1418690A CN1418690A (zh) | 2003-05-21 |
CN1194741C true CN1194741C (zh) | 2005-03-30 |
Family
ID=4752348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02153750 Expired - Lifetime CN1194741C (zh) | 2002-12-04 | 2002-12-04 | 一种灯盏细辛复方药剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1194741C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100438856C (zh) * | 2004-09-07 | 2008-12-03 | 云南白药集团大理药业有限责任公司 | 益脉康分散片及其制备方法 |
CN100435811C (zh) * | 2005-01-24 | 2008-11-26 | 深圳市生物谷科技有限公司 | 一种治疗中风的药物组合物 |
CN104784236A (zh) * | 2015-04-30 | 2015-07-22 | 广西梧州三鹤药业有限公司 | 预防心脑血管疾病的中药组合物 |
CN104825627B (zh) * | 2015-05-05 | 2018-06-22 | 山东瑞安药业有限公司 | 一种治疗心绞痛的口服凝胶制剂及其制备方法 |
CN114681563B (zh) * | 2020-12-29 | 2023-06-06 | 云南生物谷药业股份有限公司 | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 |
-
2002
- 2002-12-04 CN CN 02153750 patent/CN1194741C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1418690A (zh) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1259935C (zh) | 一种治疗高脂血症的药物 | |
CN101214270B (zh) | 刺五加有效部位的提取物、其制备方法、其应用 | |
CN103340841B (zh) | 一种中药膜剂、其制备方法和用途 | |
CN1194741C (zh) | 一种灯盏细辛复方药剂 | |
CN111939131B (zh) | 一种治疗颈椎病的固体分散体及在制备缓释制剂中的应用 | |
CN1264533C (zh) | 一种复方丹参胶囊及制备方法 | |
CN1850167A (zh) | 一种消渴降糖滴丸及其制备方法 | |
CN102614280A (zh) | 一种具有降低血脂功效的中药组合物及其制备方法和应用 | |
CN1709451A (zh) | 一种用于治疗肝胆疾病的的叶下珠制剂及其制备方法 | |
CN1182858C (zh) | 养心茶胶囊及其制备方法 | |
CN101480472B (zh) | 调血脂的药物及生产方法 | |
CN1823943A (zh) | 一种中药脑得生浓缩丸的制备工艺 | |
CN1440804A (zh) | 一种降血脂的中药 | |
CN100467037C (zh) | 一种治疗高血压的药物及其制备方法 | |
CN102058765A (zh) | 治疗肝硬化的中药制剂及其制备方法 | |
CN1899574A (zh) | 一种防治肝癌的中药组合物及其应用 | |
CN1190211C (zh) | 一种治疗咳嗽的药物的制备工艺 | |
CN1872099A (zh) | 治疗心脑血管疾病的药物 | |
CN1360902A (zh) | 一种调脂药物及其制备方法 | |
CN1943677A (zh) | 一种中药组合物及其制备方法 | |
CN1994426B (zh) | 生脉软胶囊的制备方法及其鉴定、含量测定方法 | |
CN1857370A (zh) | 一种三七止血药物及其制备方法 | |
CN1911422A (zh) | 一种用于子宫内膜异位等症的中药组合物 | |
CN1872219A (zh) | 一种治疗头痛的软胶囊及其制备方法 | |
CN1833701A (zh) | 妇科十味胶囊及其制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20070605 Pledge (preservation): Pledge |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20080721 Pledge (preservation): Pledge registration |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20080721 Pledge (preservation): Pledge |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20090622 Pledge (preservation): Pledge registration |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20090622 Pledge (preservation): Pledge |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20100713 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY DENGZHANHUA PHARMACEUTICAL Co.,Ltd.|Shenzhen Biovalley Technology Co.,Ltd. Registration number: 2009440000568 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Erigreron Breviscapus compound preparation and medical use thereof Effective date of registration: 20100713 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY DENGZHANHUA PHARMACEUTICAL Co.,Ltd.|Shenzhen Jinshajiang Investment Co.,Ltd. Registration number: 2010990000811 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20110729 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY DENGZHANHUA PHARMACEUTICAL Co.,Ltd.|Shenzhen Jinshajiang Investment Co.,Ltd. Registration number: 2010990000811 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Erigreron Breviscapus compound preparation and medical use thereof Effective date of registration: 20110729 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: Shenzhen Jinshajiang Investment Co.,Ltd.|YUNNAN BIOVALLEY DENGZHANHUA PHARMACEUTICAL Co.,Ltd. Registration number: 2011990000293 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20120704 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: Shenzhen Jinshajiang Investment Co.,Ltd.|YUNNAN BIOVALLEY DENGZHANHUA PHARMACEUTICAL Co.,Ltd. Registration number: 2011990000293 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Erigreron Breviscapus compound preparation and medical use thereof Effective date of registration: 20120704 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY DENGZHANHUA PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000347 |
|
C56 | Change in the name or address of the patentee |
Owner name: YUNNAN BIOVALLEY PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: YUNNAN BIOLOGICAL VALLEY BREVISCAPIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 650224 Yunnan city of Kunming province Beijiao Palace Patentee after: YUNNAN BIOVALLEY PHARMACEUTICAL Co.,Ltd. Address before: 650224 Yunnan city of Kunming province Beijiao Palace Patentee before: YUNNAN BIOVALLEY DENGZHANHUA PHARMACEUTICAL Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20130806 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000347 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Erigreron Breviscapus compound preparation and medical use thereof Effective date of registration: 20130806 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY PHARMACEUTICAL Co.,Ltd. Registration number: 2013990000546 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20130806 Registration number: 2012990000347 Pledgor after: YUNNAN BIOVALLEY PHARMACEUTICAL Co.,Ltd. Pledgor before: YUNNAN BIOVALLEY DENGZHANHUA PHARMACEUTICAL Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20140821 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY PHARMACEUTICAL Co.,Ltd. Registration number: 2013990000546 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Erigreron Breviscapus compound preparation and medical use thereof Effective date of registration: 20140822 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY PHARMACEUTICAL Co.,Ltd. Registration number: 2014990000692 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150708 Granted publication date: 20050330 Pledgee: Agricultural Bank of China Limited by Share Ltd. Shenzhen central sub branch Pledgor: YUNNAN BIOVALLEY PHARMACEUTICAL Co.,Ltd. Registration number: 2014990000692 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050330 |